Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Liu

Showing results (191-200 of 234) with videos related to

Pageof 24
Sort By:
Arxiv|June 3, 2024
On the acceptance, commissioning, and quality assurance of electron FLASH unitsAllison Palmiero, Kevin Liu, Julie Colnot, et al.
Medical Physics|October 27, 2024
On the acceptance, commissioning, and quality assurance of electron FLASH unitsAllison Palmiero, Kevin Liu, Julie Colnot, et al.
European Journal of Pharmacology|October 24, 2009
Discovery of a novel class of targeted kinase inhibitors that blocks protein kinase C signaling and ameliorates retinal vascular leakage in a diabetic rat modelStephan Grant, Phong Tran, Qin Zhang, et al.
European Journal of Haematology|September 30, 2010
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA studyMeletios A Dimopoulos, Maria-Victoria Mateos, Paul G Richardson, et al.
Blood|July 5, 2019
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myelomaSaad Z Usmani, Hareth Nahi, Maria-Victoria Mateos, et al.
Heart Rhythm|September 21, 2019
Renal denervation as adjunctive therapy to cardiac sympathetic denervation for ablation refractory ventricular tachycardiaJason S Bradfield, Justin Hayase, Kevin Liu, et al.
Nature Communications|May 23, 2019
ZFYVE21 is a complement-induced Rab5 effector that activates non-canonical NF-κB via phosphoinosotide remodeling of endosomesCaodi Fang, Thomas D Manes, Lufang Liu, et al.
Cancers|March 28, 2026
Initial Evaluation of Feasibility and Cutaneous Toxicity of Electron FLASH Radiotherapy Using a Standard-of-Care Fractionation Scheme in a Porcine Skin ModelElise Konradsson, Kevin Liu, Safee Baig, et al.
Health Physics|March 27, 2019
The Effects of Radiation and Emitted Light Transport on the Positional Response of 11 cm × 42.5 cm × 5.5 cm NaI(Tl) DetectorsJordan D Noey, Jeffery B Xiao, Angela DiFulvio, et al.
Clinical Pharmacokinetics|October 7, 2017
Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple MyelomaXiaoyu Yan, Pamela L Clemens, Thomas Puchalski, et al.
Pageof 24

Showing results (191-200 of 234) with videos related to

Sort By:
Pageof 24
Arxiv|June 3, 2024
On the acceptance, commissioning, and quality assurance of electron FLASH unitsAllison Palmiero, Kevin Liu, Julie Colnot, et al.
Medical Physics|October 27, 2024
On the acceptance, commissioning, and quality assurance of electron FLASH unitsAllison Palmiero, Kevin Liu, Julie Colnot, et al.
European Journal of Pharmacology|October 24, 2009
Discovery of a novel class of targeted kinase inhibitors that blocks protein kinase C signaling and ameliorates retinal vascular leakage in a diabetic rat modelStephan Grant, Phong Tran, Qin Zhang, et al.
European Journal of Haematology|September 30, 2010
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA studyMeletios A Dimopoulos, Maria-Victoria Mateos, Paul G Richardson, et al.
Blood|July 5, 2019
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myelomaSaad Z Usmani, Hareth Nahi, Maria-Victoria Mateos, et al.
Heart Rhythm|September 21, 2019
Renal denervation as adjunctive therapy to cardiac sympathetic denervation for ablation refractory ventricular tachycardiaJason S Bradfield, Justin Hayase, Kevin Liu, et al.
Nature Communications|May 23, 2019
ZFYVE21 is a complement-induced Rab5 effector that activates non-canonical NF-κB via phosphoinosotide remodeling of endosomesCaodi Fang, Thomas D Manes, Lufang Liu, et al.
Cancers|March 28, 2026
Initial Evaluation of Feasibility and Cutaneous Toxicity of Electron FLASH Radiotherapy Using a Standard-of-Care Fractionation Scheme in a Porcine Skin ModelElise Konradsson, Kevin Liu, Safee Baig, et al.
Health Physics|March 27, 2019
The Effects of Radiation and Emitted Light Transport on the Positional Response of 11 cm × 42.5 cm × 5.5 cm NaI(Tl) DetectorsJordan D Noey, Jeffery B Xiao, Angela DiFulvio, et al.
Clinical Pharmacokinetics|October 7, 2017
Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple MyelomaXiaoyu Yan, Pamela L Clemens, Thomas Puchalski, et al.
Pageof 24